ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.24
0.03%
US Tech 100
19,477.20
-0.52%
S&P 500
5,745.76
0.01%
US Dollar vs CAD
1.35094
0.24%
Bitcoin
66,117.23
1.43%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) News

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KZIA
DateTimeSourceHeadlineSymbolCompany
09/23/20248:27AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/23/20248:26AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/23/20248:25AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/23/20248:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
09/23/20247:30AMPR Newswire (US)Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
09/13/20248:14AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/13/20248:12AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/13/20248:10AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
09/13/20248:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
09/12/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
09/12/20246:30AMPR Newswire (US)KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERNASDAQ:KZIAKazia Therapeutics Ltd
08/12/20246:28PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
07/10/20249:35AMAllPennyStocks.comBiotech Experiences Strong Open Following Major AnnouncementNASDAQ:KZIAKazia Therapeutics Ltd
07/10/20248:28AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
07/10/20248:28AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
07/10/20248:26AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
07/10/20248:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
07/10/20246:30AMPR Newswire (US)Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaNASDAQ:KZIAKazia Therapeutics Ltd
06/27/20247:15AMPR Newswire (US)KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERNASDAQ:KZIAKazia Therapeutics Ltd
06/04/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
06/04/20243:06PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
05/29/20247:55AMEdgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
05/23/20241:41PMPR Newswire (US)Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementNASDAQ:KZIAKazia Therapeutics Ltd
05/23/20246:03AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
05/23/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
05/17/20243:07PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
05/17/20243:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
05/01/20247:45AMPR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
03/21/20247:52AMPR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
03/13/20247:00AMPR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

Your Recent History

GATE
TSHPUSDT
12Ships
BIT
NSCIT00126D0
Spain
NASDAQ
AAXAVXX
Morgan Stanley Finance L...
NASDAQ
QCBC
Quaker City Bancorp
USOTC
NRGOF
Pinnacle Silver and Gold (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved